Voyager’s senior management team to highlight lead program VY-AADC for Parkinson’s disease, integration of novel capsid and delivery optimization efforts, and pipeline programs from the ALS, Huntington’s disease, Friedreich’s ataxia, anti-Tau antibody and severe chronic pain programs